Registrant : Organisation or self-employed individual
| Name/company name: |
Grünenthal GmbH |
| Acronym: |
Grünenthal
|
| Legal status: |
Gesellschaft mit beschränkter Haftung
|
| Website address: |
http://www.grunenthal.com
|
Sections
| Section: |
II - In-house lobbyists and trade/professional associations |
| and more precisely: |
Companies & groups |
Person with legal responsibility
| Surname, Name: |
Mr
Harald F. Stock
|
| Position: |
Chief Executive Officer |
Permanent person in charge of EU relations
| Surname, Name: |
Mr
Konrad Labuschagne
|
| Position: |
Governmental Affairs and Health Policy |
Contact details:
| Contact details of organisation's head office: |
6 Zieglerstraße
Aachen D-52099
GERMANY
|
| Telephone number: |
(+49) 241 569 0 |
| Fax number: |
(+49) 241 569 3474 |
| Other contact information: |
|
Goals / remit
| Goals / remit of the organisation: |
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last five research-oriented pharmaceutical corporations with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 25 percent of revenues in 2011. Grünenthal’s research and development strategy concentrates on select fields of therapy and state-of-the-art technologies. We focus on the intensive search for new ways to treat pain better, more effectively and with fewer side-effects than before. Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries and today approx. 4,200 employees are working for the Grünenthal Group worldwide. In 2011, Grünenthal achieved revenues of €947 mn. More information: www.grunenthal.com
|
|
The organisation's fields of interests are:
|
|
Number of persons engaged in activities falling under the scope of the Transparency Register
| Number of persons: |
1
|
|
Complementary information:
|
|
Persons accredited for access to European Parliament premises
| First name
|
Surname
|
Start Date |
End Date |
|
Konrad
|
Labuschagne
|
19/06/12
|
31/05/13
|
|
Kristina
|
Barinka
|
02/03/13
|
28/03/14
|
Activities
Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:
|
Grünenthal supports the multistakeholder platform "Sociatal Impact of Pain" (SIP, www.sip-platofrm.eu). Furthermore Grünenthal activities in Brussels deal with issues related to healthcare, pain care, pharmaceuticals, innovation and research and intellectual property.
|
Fields of interest for e-mail alerts on consultations and roadmaps;
| Fields declared by the organisation: |
- Competition
- Customs
- Economic and Financial Affairs
- Employment and Social Affairs
- Enlargement
- Enterprise
- General and Institutional Affairs
- Humanitarian Aid
- Internal Market
- Public Health
- Regional Policy
- Research and Technology
- Taxation
- Trans-European Networks
|
Networking
Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.
|
Grünenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA)
|
Financial data
| Financial year: |
01/2010
-
01/2011
|
|
Estimated costs to the organisation directly related to representing interests to EU institutions in that year:
|
< 50000
€
|
|
Amount and source of funding received from the EU institutions in financial year n-1 of registration
|
|
Procurement:
|
0 €
|
|
Grants:
|
0 €
|
Other (financial) information provided by the organisation:
|
|
|
